Tomkiel Melissa M.'s Form 4/A amendment
AmendedStrata Critical Medical, Inc. (SRTA) · filed Apr 17, 2024
- Accession no.
- 0001779128-24-000057
- Filed
- Apr 17, 2024
- Trade date
- Apr 3, 2024
- Filing delay
- 14 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Apr 5, 2024
This filing lists 1 non-derivative transaction. Open-market sales total $38.5K. It was filed 14 days after the trade.
This amendment replaces 0001779128-24-000053 (filed Apr 5, 2024).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tomkiel Melissa M.CIK 0001859484 | Officer (President and General Counsel) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 3, 2024 | Class A common stock, $0.0001 par value per share | SSaleDisposed | −11,734 | $3.28F3 | −$38,487.52 | 1,302,223 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The original Form 4, filed on April 5, 2024, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a sale that occurred on April 3, 2024 as a total of 22,836 shares sold when in fact only 11,734 shares of the Issuer's common stock were sold. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects an increase in the number of shares reported as beneficially owned by the reporting person by 11,102 shares.
- F2
Represents shares automatically sold to cover tax withholding obligations associated with the vesting of a restricted stock unit award.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.175 to $3.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Referenced by the price of 1 transaction in Table I.